Business
Real-World Evidence Confirms Immediate and Ongoing Performance of the t:slim X2 Insulin Pump with Control-IQ Technology in Children and Adults
BARCELONA, Spain--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced real-world
About this update from Tandem Diabetes Care, Inc.
[{"type":"text","content":" BARCELONA, Spain--(BUSINESS WIRE)--\nTandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced real-world data confirming that use of the t:slim X2™ insulin pump with Control-IQ® advanced hybrid closed-loop technology resulted in immediate and ongoing improvements in glycemic control, quality of life outcomes, and user-reported reduced burden of diabetes management.1 The data was presented today at the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Barcelona, Spain.\n\n“Experience matters. And with more than 60 million real-world patient-use days in the United States, and even more globally, our Control-IQ technology continues to set the high-bar in advanced automated insulin dosing,” said Jordan Pinsker, MD, Vice President and Medical Director at Tandem Diabetes Care. “The data presented at ATTD further reinforces the strength of Control-IQ technology in both clinical- and patient-reported outcomes, and we are proud of the positive impact and increased freedom people report experiencing through the use of our technology solutions.”\n\nU.S. Presentations Including Control-IQ Technology\n\nMuch of the evidence presented at ATTD comes from the Control-IQ Observational (CLIO) study, an ongoing real-world evaluation of people with type 1 diabetes using the t:slim X2 pump with Control-IQ technology.\n\nControl-IQ Observational (CLIO) Longitudinal Study Results at 9 Months\n\nThis analysis included data from 1,913 participants from the CLIO Study who had at least 9 months experience using Control-IQ technology, and examined relationships between glycemic metrics, participants’ age, and previous insulin delivery method.\n\nThe data demonstrated successful adoption of Control-IQ technology by people previously using multiple daily injections (MDI) or other devices. In addition, it demonstrated the efficacy of long-term use across all age cohorts ranging from pediatrics to 65-plus.2\n\nCLIO Study Patient Reported Outcomes (PRO) at 6 Months\n\nThis analysis included data from 2,062 CLIO participants and compared PROs before initiating and after 6 months of use of Control-IQ technology.\n\nData demonstrated Control-IQ technology users experienced improved quality of life, reduced diabetes burden, and higher satisfaction with diabetes therapy...